TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Protein Supplement on Paraspinal Muscles in Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18-65 years~* Body mass index 18.5-30~* Candidate for the elective posterior spine fusion~* Without history of severe liver disorder~* Without history of Kidney disorder~* Without history of diabetes~* Without history of trauma and fracture of the vertebral~* Without history of osteoporosis~* Without history of Gastrointestinal malabsorption~* Without history of Parathyroid gland disorders~* Without taking medications that affect the metabolism of bone, such as calcitonin, bisphosphonate, corticosteroid~* No smoking~* Without history of neuromuscular diseases such as dystrophies and neurological disorders~Exclusion Criteria:~* Allergy or intolerance to protein or maltodextrine supplement~* Unwillingness to continue cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- protein supplement (Type: EXPERIMENTAL): Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
- maltodextrin (Type: PLACEBO_COMPARATOR): Control patients will be received protein diet (1.2 g/kg/day) and maltodextrin for 1 month after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Have clinically stable symptomatic heart failure (HF) (heart failure with reduced ejection fraction \[HFrEF\] and heart failure with preserved ejection fraction \[HFpEF\]): (A) For HFrEF: (a) ejection fraction (EF) less than or equal to (\<=) 40 percent (%) and (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months (B) For HFpEF: (a) EF greater than (\>) 40%; (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months, AND; (C) on a loop diuretic or spironolactone or eplerenone (mineralocorticoid receptor antagonists), in the past 18 months~* Have a baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) score of less than or equal to (\<=) 80 prior to randomization~* Be able to read and understand English~* Possess and have sole use (example: not shared with other users) of smartphone compatible with the Fitbit device~* Willing/able to wear the Fitbit device on a regular basis for the 9-month study period~Exclusion Criteria:~* Currently taking a sodium-glucose co-transporter 2 inhibitor (SGLT2i) or within the last 3 months~* History of diabetic ketoacidosis or have type 1 diabetes mellitus (T1DM)~* Have acute decompensated HF (exacerbation of symptomatic HF) requiring intravenous diuretics, inotropes, or vasodilators within the last 4 weeks~* Have stage 4 or 5 Chronic Kidney Disease (that is, estimated glomerular filtration rate \[eGFR\] \<30 milliliter per minute \[ml/min\] on dialysis) from the most recent assessment~* Have a diagnosis of hypotension within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Participants will be administered 100 milligram (mg) immediate-release, over-encapsulated tablets (as a capsule) orally once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be administered matching placebo capsules orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed patient.~* Provision of written informed consent.~* De Novo (primary) or Secondary AML.~* Not eligible for intensive induction chemotherapy because of medical, social or psychological reasons.~Exclusion Criteria:~* Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL).~* Patients with blast crisis of chronic myeloid leukaemia.~* Persistent, chronic, clinically significant toxicities from any prior anti- cancer therapy greater than CTCAE Grade 1 (except alopecia).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus~* Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be \>=7.0% and \<=10.0% at screening~* Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10 weeks prior to Visit 1 must be \>=7.0% and \<=9.0% at screening and \>=7.0% and \<=10.0% at placebo run-in~* Male and female patients on diet and exercise regimen who are pre-treated with OAD alone for at least 10 weeks prior to Visit 1 must be \>=7.0% and \<=10.0% at both screening and placebo run-in~* Age at informed consent must be \>=20 years~* BMI at screening must be \<=40 kg/m2~* Further inclusion criteria apply~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose values \>270 mg/dL (\>15.0 mmol/L) after an overnight fast during switch/washout/placebo run-in period and confirmed by a second measurement~* Patients who are drug-naïve at screening visit or treat with any of insulin, thiazolidine dione, sodium-glucose co-transporter 2 (SGLT-2) inhibitor within 10 weeks prior to informed consent.~* Acute coronary syndrome, stroke or transient ischemic attack within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal as determined during screening and/or switch/washout/placebo run-in period~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m2 (Japanese equation) as determined during screening and/or switch/washout/placebo run-in period~* Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- empagliflozin 10 mg (Type: EXPERIMENTAL): empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
- empagliflozin 25 mg (Type: EXPERIMENTAL): empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing primary liver transplantation.~* Patients older than 18 years.~* Patients with a hepatorenal syndrome type I or II~* eGFR \< 50 ml/min at the time point of transplantation~* Serum creatinine levels \> 1.5 mg/dL at the time-point of transplantation~Exclusion Criteria:~* Patients with pre-transplant renal replacement therapy \> 14 days.~* Patients with a known hypersensitivity to mTOR-inhibitors.~* Patients with a known hypersensitivity to mycophenolate acid.~* Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.~* Patients with platelets \< 50.000/nl.~* Patients with triglycerides \> 350 mg/dl and cholesterol \> 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition.~* Severe systemic infections and wound-healing disturbances prior to inclusion.~* Multiple organ graft recipients.~* Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with Sirolimus.~* Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.~* Patients under guardianship (e.g. individuals who are not able to freely give their informed consent).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed adenocarcinoma or carcinoma of the stomach, pancreas and biliary tract with unresectable, recurrence or metastatic disease.~* No prior systemic chemotherapy except adjuvant chemotherapy that has completed 6 months prior enrollment.~* Palliative RT to bone but not the primary, main tumor site is permitted.~* At least one measurable lesion over non-radiated site.~* Aged between 20 to 70 years old.~* ECOG Performance Status \<= 1.~* Life expectancy greater than 12 weeks.~* Adequate bone marrow function : absolutely neutrophil count \>= 1.5 x 109/L or WBC \>= 4 x 109/L, hemoglobin \>= 9 g/dl, platelet count 100 x 109/L~* Adequate liver function : ALT \<= 2.5 x ULN and Bilirubin \< 1.5 x ULN~* Adequate renal function: creatinine \< 1.5 x ULN and calculated eGFR\> 50 mL/min.~Exclusion Criteria:~* Major surgery within four weeks prior to study enrolment.~* Patient with Ampulla vater cancer is excluded.~* Patients with suspicious or history of CNS metastasis.~* Patients who with active or uncontrolled infections.~* Patients who have history of myocardial infarction or unstable angina within 6 months before entry.~* Patients with concomitant illness that might be aggravated by chemotherapy.~* Patients who are pregnant or with breast feeding.~* Other concomitant or previously malignancy within 3 yrs except for in situ cervix cancer or squamous cell carcinoma of the skin, stage 0-I colon or breast treated by surgery only and without evidence of relapsed tumor.~* Mental status is not fit for clinical trial~* Fertile men and women unless using a reliable and appropriate contraceptive method.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOLAR (Type: EXPERIMENTAL): Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60\~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male subjects~* no evidence of disease~* no history of gastrointestinal or endocrine disorders~Exclusion Criteria:~* alcohol and drug abuse~* history of gastrointestinal or endocrine disorders~* female subjects

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ORAL GLP-1, TABLET (Type: ACTIVE_COMPARATOR): None
- Oral PYY3-36 (Type: ACTIVE_COMPARATOR): None
- Oral GLP-1 plus oral PYY3-36 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PF-06741086 Multiple Dose Study in Severe Hemophilia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%), including patients with inhibitors to Factor VIII or Factor IX~* Episodic (on-demand) treatment regimen prior to screening~* At least 6 acute bleeding episodes during the 6-month period prior to screening~Exclusion Criteria:~* Known coronary artery, thrombotic, or ischemic disease~* Currently receiving treatment for acute bleeding episodes with APCC and cannot substitute treatment with rFVIIa

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- PF-06741086 (Cohort 1) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 2) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 3) (Type: EXPERIMENTAL): None
- PF-06741086 (Cohort 4) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive patients older than 18 years who are scheduled to undergo diagnostic or therapeutic ERCP will be recruited~Exclusion Criteria:~* Patients will be excluded if they have acute pancreatitis during the 2 weeks before ERCP, a history of chronic pancreatitis, previous sphincterotomy, or if they refuse to participate the study protocol. Patients will be also excluded if they undergo ERCP, for procedures such as stone removal following previous sphincterotomy, change or removal of previous biliary stents, or surveillance biopsy after endoscopic papillectomy without pancreatography, which are considered to carry minimal risks of post-ERCP pancreatitis. Patients with high risk of fluid overload (heart failure, more than NYHA II; renal insufficiency, creatinine clearance \<40ml/min; liver cirrhosis; or hypoxemia, SaO2 \<90%; signs of pulmonary edema) are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- vigorous hydration arm (Type: EXPERIMENTAL): Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.~* Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour
- standard hydration arm (Type: ACTIVE_COMPARATOR): Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have used and/or desired to us an artificial tear substitute for dry eye symptoms within 6 months prior to Visit 1~Exclusion Criteria:~* Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such as blepharoplasty) in either eye within three months or refractive surgery (e.g. laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1~* Have a history or presence of an ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed.~* Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)~* Have a known hypersensitivity to any of the procedural agents or study drug components~* Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OC-01 0.1%, 0.6 mg/ml (Type: ACTIVE_COMPARATOR): OC-01 (varenicline) nasal spray, 0.6 mg/mL
- OC-01 0.2%, 1.2 mg/ml (Type: ACTIVE_COMPARATOR): OC-01 (varenicline) nasal spray, 1.2 mg/mL
- Placebo (Type: PLACEBO_COMPARATOR): vehicle control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2 to 16 years~* New patients presenting to The Hospital for Sick Children~* Clinical confirmation of alopecia areata~* Hair loss between 10 -75%~Exclusion Criteria:~* Skin or medical problems requiring use of oral steroids~* Immunosuppressants or PUVA for 4 weeks prior to the study~* Use of inhaled and or intranasal steroids for 14 days prior to trial~* Topical medicaments for 7 days prior to the trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Hydrocortisone 1% (Type: EXPERIMENTAL): None
- Clobetasol Propionate 0.05% (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete